Related Experiment Video
Updated: Jul 4, 2025
07:29
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
10.8K
Reversible Pulmonary Hypertension Related to Hyperthyroidism: A Case Report
Joana Silva1, Ana Carvoeiro2, Paula Cerqueira1
1Internal Medicine, ULSAM (Unidade Local de Saúde do Alto Minho) Hospital Conde de Bertiandos, Ponte de Lima, PRT.
Cureus
|January 31, 2024
Summary
Graves' disease can cause pulmonary hypertension (PH) in young women. Treating hyperthyroidism resolved PH, highlighting the need to investigate thyroid function in PH patients.
Area of Science:
- Cardiology
- Endocrinology
- Pulmonology
Background:
- Pulmonary hypertension (PH) requires systematic etiological assessment.
- Graves' disease is an autoimmune disorder affecting the thyroid gland.
Observation:
- A young woman with Graves' disease presented with exertional dyspnea and fatigue.
- Echocardiography revealed pulmonary hypertension, tricuspid regurgitation, and a patent foramen ovale (PFO).
- Investigations for common PH causes were negative.
Findings:
- Treatment for hyperthyroidism (methimazole, radioiodine ablation) led to a euthyroid state and symptom improvement.
- Follow-up assessments confirmed the resolution of pulmonary hypertension and normalization of cardiac parameters.
- Right heart catheterization validated the absence of PH.
Implications:
- Hyperthyroidism, via high cardiac output and endothelial injury, is a potential reversible cause of pulmonary hypertension.
- Thyroid function assessment should be integral to the etiological workup of suspected PH.
- Cardiovascular manifestations of hyperthyroidism, including PH, may resolve with thyroid-specific treatment.
Keywords:
graves diseasehyperthyroidismreversible pulmonary hypertensionright cardiac catheterizationright ventricular dysfunctiontricuspid regurgitationMore Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
180
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
01:27Pneumothorax-II
150
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
150
01:26Pneumothorax-I
209
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
209